Skip to main content
RenovoRx (Nasdaq: RNXT) logo

Medical Science Liaison

RenovoRx (Nasdaq: RNXT)
September 11, 2026
Full-time
Remote
Worldwide
$210,000 - $210,000 USD yearly
Medical Affairs
Role: Medical Science Liaison (MSL) supporting innovative targeted oncology therapies, including intra-arterial gemcitabine delivery via RenovoCath. Objectives: build scientific relationships with oncology healthcare professionals, educate on TAMP technology, gather clinical insights, and support clinical development. Responsibilities: develop peer-to-peer relationships with oncologists across medical, surgical, and radiation specialties; deliver compliant medical education and training; participate in scientific meetings and congresses; collaborate with cross-functional teams (Sales, Marketing, R&D) to align messaging and strategies; collect and synthesize field insights to inform company strategies. Requirements: Master's degree in life sciences; at least 5 years as an MSL, preferably in GI medical oncology supporting drug-device combos or delivery systems; deep knowledge of oncology guidelines (NCCN, ASCO), emerging therapies, and clinical practices; excellent communication skills, relationship-building, and ability to work independently; proficiency with CRM tools. Preferred: advanced degrees (PhD, PharmD, MD), experience with biomarker technologies (ctDNA, oncolytic viruses, CAR-T), and familiarity with clinical trial stages (Phase III). High-Value: oncology, targeted therapies, intra-arterial drug delivery, clinical education, KOL engagement, and field intelligence gathering. Work setup: full-time, remote based in the U.S., with up to 90% travel to clinical sites, conferences, and meetings.